Clin2
NCT07687212Possibly a fitNot yet recruiting

Heart failure drug combined with probiotics for older adults

Heart Failure, Preserved Ejection Fraction

Part of Heart & circulation clinical trials.

This trial tests whether adding a heart failure medicine (SGLT-2 inhibitor) alongside probiotics helps older adults with a specific type of heart failure (HFpEF). It aims to improve symptoms and quality of life.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
162 people
Ages
60 years and older
Study type
Interventional

Who can take part

  • Age 60 or older
  • Diagnosed with heart failure with preserved ejection fraction (HFpEF) within the past 6 months
  • Currently in stable heart failure, no recent hospitalizations or acute episodes
  • Not taken SGLT-2 inhibitors in the last 6 months or probiotics in the last 3 months
  • Able to understand the trial and give informed consent

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06350487Not yet recruiting· Phase 4
Enavogliflozin for heart failure with preserved pumping ability

This trial tests a new medication called enavogliflozin (an SGLT2 inhibitor) to see if it helps people with a specific type of heart failure where the heart pumps normally but is stiff. You may be able to join if you have stable heart failure, are not on another SGLT2 inhibitor, and have good kidney function.

Seoul
NCT07628777Not yet recruiting· Phase 1/Phase 2
Gut Bacteria Transplant for Heart Failure in Older Adults

This study tests whether transplanting healthy gut bacteria can help older adults with heart failure that has a preserved ejection fraction (HFpEF). Researchers think the gut microbiome may play a role in heart function and hope this treatment could improve symptoms and quality of life.

Xi’an, Shanxi
NCT05138575Recruiting· Phase 2
Testing SGLT2 pill and potassium nitrate for heart failure with preserved EF

This trial studies whether two medicines—an SGLT2 inhibitor and potassium nitrate—can improve symptoms and heart function in people with heart failure with preserved ejection fraction (HFpEF). It focuses on people who still have signs of “stiff” or high filling pressure in the heart despite a normal-ish ejection fraction.

Philadelphia, Pennsylvania
NCT07731490Recruiting
Early detection and treatment of heart failure

This trial tests if a medication can prevent heart failure in older adults who are at risk. It is for people aged 65 or older who are having certain heart procedures or a major surgery.

Vienna
NCT06507657Recruiting· Early Phase 1
Empagliflozin for heart health in older adults

This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.

Minneapolis, Minnesota
NCT06024746Recruiting· Phase 3
Finerenone plus SGLT2i for hospitalized heart failure

This trial tests whether adding two heart medicines together (finerenone and an SGLT2 inhibitor) helps people who are in the hospital for heart failure recover better. It may be an option for you if you are currently hospitalized and your heart stress markers are high.

Fairhope, Alabama

Hear when a new Heart Failure, Preserved Ejection Fraction trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.